Molecular Pathology of
Endometrial Cancer
Endometrial Cancer
|
Molecular Pathology of Endometrial Cancer |
| Home | • | About | • | Our Team | • | Expert Opinion | • | CuraBase Workspace | • | Contact |
|
| Region | Incidence Overall | Incidence Males | Incidence Females | Deaths Overall | Deaths Males | Deaths Females |
|---|---|---|---|---|---|---|
| USA | 43470 | 0 | 43470 | 7950 | 0 | 7950 |
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FGFR-2 (k-sam) | Receptor Tyrosine Kinase Signaling |
primary uterine tumor endometrioid subtype | 16% | |||||||||
| p53 | p53 Tumor Suppressor Pathway |
high-grade endometrioid adenocarcinomas | 17% | rare in low-grade endometrioid adenocarcinomas | ||||||||
| p53 | p53 Tumor Suppressor Pathway |
non-endometrioid adenocarcinomas | 54 - 85% | Immunohistochemical overexpression of p53 | ||||||||
| Pi3-kinase | PI3-Kinase Signaling |
endometrial carcinoma | 30 - 36% | frequent coexistence of PIK3CA and PTEN mutations in endometrial carcinomas | ||||||||
| PTEN | PI3-Kinase Signaling |
endometrial carcinomas | 30 - 54% | more frequent in endometrioid adenocarcinomas than in non-endometrioid adenocarcinomas | ||||||||
| PTEN | PI3-Kinase Signaling |
endometrial carcinomas | 68% | absence of protein expression | ||||||||
| PTEN | PI3-Kinase Signaling |
endometrial carcinomas | 19% |
| See Clinical Trials in in the TTC Database |
| CANCER.GOV PDQ® - Standard Treatments for Endometrial Cancer |